Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Change in Accured Expenses (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Change in Accured Expenses for 16 consecutive years, with $38.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 857.26% year-over-year to $38.1 million, compared with a TTM value of $82.8 million through Dec 2025, up 601.07%, and an annual FY2025 reading of $82.8 million, up 601.07% over the prior year.
  • Change in Accured Expenses was $38.1 million for Q4 2025 at Amicus Therapeutics, up from $30.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $38.1 million in Q4 2025 and bottomed at -$40.2 million in Q1 2021.
  • Average Change in Accured Expenses over 5 years is $5.8 million, with a median of $7.3 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses skyrocketed 1204.27% in 2021, then crashed 33904.17% in 2024.
  • Year by year, Change in Accured Expenses stood at $29.5 million in 2021, then crashed by 207.95% to -$31.8 million in 2022, then skyrocketed by 125.42% to $8.1 million in 2023, then tumbled by 162.23% to -$5.0 million in 2024, then skyrocketed by 857.26% to $38.1 million in 2025.
  • Business Quant data shows Change in Accured Expenses for FOLD at $38.1 million in Q4 2025, $30.6 million in Q3 2025, and $10.4 million in Q2 2025.